Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO® (mogamulizumab) at EORTC 2023.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today presented data from a preliminary analysis of the TELLOMAK Phase 2 trial demonstrating clinical activity and a favorable safety profile for lacutamab, a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, in patients with advanced Sézary syndrome, a form of T cell lymphoma. The data were presented during the 2022 ASH (American Society Hematology) Annual Meeting, in New Orleans (United States).
Kyowa Kirin's Mogamulizumab Receives Supplemental Approval in the U.S.
NICE has recommended POTELIGEO (mogamulizumab), manufactured by Kyowa Kirin, as a treatment option for adults in England in Wales with the ultra-rare blood cancers mycosis fungoides (MF) and Sezary syndrome (SS), two forms of cutaneous T-cell lymphoma (CTCL). The treatment is approved for use after two prior systemic treatments for adults living with MF, and one for adults living with SS.
GALASHIELS, Scotland--(BUSINESS WIRE)--Kyowa Kirin International PLC (Kyowa Kirin), a wholly owned subsidiary of Kyowa Kirin Co., Ltd., today announced a new study of real world data showing higher response rates than previously seen in people living with cutaneous T-cell lymphoma (CTCL) treated with POTELIGEO® (mogamulizumab). The findings, from a retrospective observational study of French CTCL patients, showed that the best overall response rate in the real-life study was 58.5 per cent, compared to 35 per cent seen in the MAVORIC trial.1,2 The MAVORIC study was the pivotal Phase 3 trial that investigated treatment with POTELIGEO® compared to an active comparatora in previously treated adult patients with mycosis fungoides (MF) and Sézary syndrome (SS), two types of CTCL.
NICE to reassess Kyowa Kirin’s Poteligeo
The National Institute for Health and Care Excellence (NICE) has upheld an appeal lodged by Kyowa Kirin, Lymphoma Action and Leukaemia Care, and the UK Cutaneous Lymphoma Group (UKCLG) as part of the Single Technology Appraisal for POTELIGEO® (mogamulizumab) for the treatment of adults with the ultra-rare blood cancers mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
The National Institute for Health and Care Excellence (NICE) has upheld an appeal lodged by Kyowa Kirin, Lymphoma Action and Leukaemia Care, and the UK Cutaneous Lymphoma Group (UKCLG) as part of the Single Technology Appraisal for POTELIGEO® (mogamulizumab) for the treatment of adults with the ultra-rare blood cancers mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
Kyowa Kirin International PLC (Kyowa Kirin), a wholly owned subsidiary of Kyowa Kirin Co., Ltd., today announced a new analysis of data showing statistically significant improvements in quality of life in cutaneous T-cell lymphoma (CTCL) patients treated with mogamulizumab with blood involvement, compared to vorinostat.1 The new findings from the MAVORIC trial compared the impact of treatment with POTELIGEO® (mogamulizumab) and vorinostat by patient blood tumour burden in adult patients with mycosis fungoides (MF) and Sézary syndrome (SS), two types of CTCL.
NICE is not recommending NHS funding for Kyowa Kirin's Poteligeo (mogamulizumab) as a treatment for mycosis fungoides or Sézary syndrome for adults who have had at least one previous systemic treatment.